Novavax

Novavax, Inc., founded in 1987 and headquartered in Gaithersburg, Maryland, is a biotechnology company focused on developing novel vaccines to combat infectious diseases globally. Utilizing proprietary virus-like particle (VLP) technology, Novavax aims to address a wide range of health threats. The company's core mission is to protect global health through innovative vaccine solutions, with a vision of ensuring vaccine access and supporting environmental and governance standards. Novavax's product portfolio includes vaccines for diseases such as COVID-19, with a particular emphasis on protein-based vaccine options.

Notable figures affiliated with Novavax include CEO John Jacobs and R&D leader Filip Dubovsky. The company is publicly traded on Nasdaq under the ticker NVAX and is a component of the Russell 2000 index. Key achievements include filing for FDA authorization for an updated protein-based COVID-19 vaccine and generating a revenue of $983.7 million in 2023. With a workforce of over 1,500 employees, Novavax has made a significant impact on global health through its innovative vaccine development efforts.